StockData
Prenetics Global Ltd logo

Prenetics Global Ltd (PRE) stock

PRENasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as PRENW
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026Score 10/30
$16.72−0.92 (-5.22%)

Close on Nov 12, 2026Market cap $282.14MP/E –Yield –

Earnings

Prenetics Global's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q4 FY2025
$36.60M
+248.6% on a year earlier
EPS, Q4 FY2025
-$1.75
Latest guidance
Issued
Feb 18, 2026 · 3 items

Quarterly results

Revenue and earnings per share from each of Prenetics Global's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2025ended Dec 31, 2025Feb 18, 2026before the open$36.60M+248.6%-$1.75Release
Q4 FY2024ended Dec 31, 2024Mar 5, 2025before the open$10.50M+94.4%–Release
Q4 FY2023ended Dec 31, 2023Apr 1, 2024before the open$5.40M–-$1.57Release
Q4 FY2022ended Dec 31, 2022Mar 14, 2023during market hours–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Prenetics Global's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
RevenueFY2025$73.00M – $85.00M–NewMar 5, 2025
Adjusted EBITDA lossnon-GAAPFY2025-$15.00M – -$13.00M–NewMar 5, 2025
IM8 revenue guidanceFY2026$180.00M – $200.00M–NewFeb 18, 2026
IM8 gross marginsFY202660%–NewFeb 18, 2026
Adjusted EBITDA lossnon-GAAPFY2026$16.00M – $20.00M–NewFeb 18, 2026

Guidance history

Every forecast Prenetics Global put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Feb 18, 2026Adjusted EBITDA lossFY2026$16.00M – $20.00MNew
Feb 18, 2026IM8 gross marginsFY202660%New
Feb 18, 2026IM8 revenue guidanceFY2026$180.00M – $200.00MNew
Mar 5, 2025Adjusted EBITDA lossFY2025-$15.00M – -$13.00MNew
Mar 5, 2025Adjusted EBITDA lossQ1 FY2025-$6.00M – -$5.50MNew
Mar 5, 2025RevenueQ1 FY2025$11.50M – $13.00MNew
Mar 5, 2025RevenueFY2025$73.00M – $85.00MNew
Apr 1, 2024revenue projectionsFY2024$33.00M – $36.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Prenetics Global filed with the SEC as exhibits to Form 8-K or 6-K

  1. Prenetics’ IM8 and Authentic Brands Group Announce 10-Year Exclusive Global Partnership to Create Care Bears by IM8; Authentic to Become Strategic Shareholder in Prenetics
    6-K
  2. (b) “ Business ” shall be defined as Company’s business operation relating to the Licensed Products and otherwise under this Agreement.
    6-K
  3. Prenetics’ IM8 Names Brian J. Rosin as Successor Chief Financial Officer
    6-K
  4. Photo: IM8 co-founder David Beckham; two-time NBA champion Chris Bosh; IM8 chief of staff and brand partnerships Samantha Kwok; and NBA executives (Credit: NBA)
    6-K
  5. Prenetics’ IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results
    6-K
  6. Prenetics’ IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership
    6-K
  7. 6-K exhibit EX-99.1
    6-K
  8. Shareholder Letter — Q2 2026
    6-K
  9. Q2 2026 Investor Presentation 1
    6-K
  10. Prenetics, Parent of IM8, Appoints II Ranked, Caroline Levy, Veteran Wall Street Consumer Analyst as Independent Director
    6-K
  11. RISK FACTORS RELATING TO GENERAL CATALYST FINANCING ARRANGEMENT
    6-K
  12. Dated as of July 13, 2026
    6-K
  13. Dated as of July 13, 2026
    6-K
  14. Prenetics’ IM8 Secures $1 Billion Growth Financing from General Catalyst’s Customer Value Fund (CVF)
    6-K
  15. 6-K exhibit EX-99.2
    6-K

See a number that looks wrong?